 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- acetazolamide / Generic mfg., dichlorphenamide / Generic mfg.
Semaglutide (S) Completely Reverses the Severe Chronic Myopathy of Hyperkalemic Periodic Paralysis (Exhibit Hall, Convention Center) - Sep 23, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_1417;
By altering insulin signaling and skeletal muscle physiology, S increases intracellular potassium storage and decreases myopathy in HPP. S is an excellent & novel once weekly option that treats not just the hyperkalemic periodic paralysis but also the skeletal muscle weakness in a multimodal way.SPPBSPPBPre S4 mo7 mo12 moSide by Side Test (sec/ score)4/029/1>30/1180/1Semi Tandem Gait Test (sec/ score)1/015/1>30/145/1Tandem Gait Test (sec/ score)0/020/2>20/215/23 Meter Standard Gait Test (sec/ score)10.1/04.25/32.87/43.52/43 Meter Fast Gait Test (sec/ score)6.8/03.0/41.8/43.25/4Repeat Chair Stand Test (sec/ #/ score)0/0/025.1/5/115.4/5/220.5/5/1Total Score (normal >12)0121413BMI (kg/m2)36.533.231.329.2
- | dichlorphenamide / Generic mfg.
Journal: Exploring bioactive compounds from a symbiotic bacterial strain of Spongiobacter sp. (Pubmed Central) - Oct 12, 2023
Using LC-MS analysis bioactive compounds Dichlorphenamide, Amifloxacin and Carbenicillin are identified in both positive and negative mode...EA276. Our results highlighted the significance of marine flora inhabiting sponges from the Red Sea as potential source of bioactive compounds and plant growth hormones of biological and agricultural significance.
- || Keveyis (dichlorphenamide) / Strongbridge
Review, Journal: Pyrazole/pyrazoline as an excellent pharmacophore in the design of carbonic anhydrase inhibitors (2018-2022). (Pubmed Central) - Jan 5, 2023
Hence, research that took place in the field of drug design and discovery of CA inhibition has been systematically reviewed and collated. Alongside, the structure-activity relationship has been described, followed by a description of the most potent molecules and their structural features.
- || Keveyis (dichlorphenamide) / Strongbridge
Clinical, Review, Journal: Drug repurposing in skeletal muscle ion channelopathies. (Pubmed Central) - Dec 16, 2022
Thus, ongoing research aims at the identification of repurposed drugs alternative to mexiletine and dichlorphenamide to allow personalization of treatment. This review highlights how drug repurposing may represent an efficient strategy in rare diseases, allowing reduction of drug development time and costs in a context in which the return on investment may be particularly challenging.
- | Keveyis (dichlorphenamide) / Strongbridge
Preclinical, Journal: Neuroprotective Effects of Carbonic Anhydrase Inhibition and Cyclic Adenosine Monophosphate Activation in Mouse Model of Transient Global Cerebral Ischemia and Reperfusion. (Pubmed Central) - Oct 29, 2022
In this investigation, the potential of dichlorphenamide (CAI) and the role of cAMP against ischemia-reperfusion injury were evaluated using a transient global cerebral I/R (tGCI/R) model...However, DCPA and FSK in combination showed much enhanced therapeutic outcomes against tGCI/R. Therefore, CA and cAMP present novel targets that may retard the progress of a transient ischemic attack to a full-blown stroke.
- | Keveyis (dichlorphenamide) / Strongbridge
Journal: The role of nephrologists in management of hypokalemic periodic paralysis: a case report. (Pubmed Central) - Feb 19, 2022
This case demonstrates the crucial role nephrologists can play, not only in the diagnosis of hypokalemic periodic paralysis, but also in the ongoing management of this condition. Patients should be advised to regularly follow up with their nephrology team for evaluation due to the risk of developing myopathy.
- | Keveyis (dichlorphenamide) / Strongbridge
Journal: Dichlorphenamide for Refractory Hyperkalemic Periodic Paralysis. (Pubmed Central) - Jan 18, 2022
Patients should be advised to regularly follow up with their nephrology team for evaluation due to the risk of developing myopathy. No abstract available
- || Keveyis (dichlorphenamide) / Strongbridge
Clinical, Review, Journal: Targeted Therapies for Skeletal Muscle Ion Channelopathies: Systematic Review and Steps Towards Precision Medicine. (Pubmed Central) - Nov 17, 2021
These studies provided limited information about the response to treatments of individual mutations or groups of mutations. A major effort is needed to perform human studies for designing a mutation-driven precision medicine in muscle ion channelopathies.
- | Keveyis (dichlorphenamide) / Strongbridge
Journal: Increased sarcolemma chloride conductance as one of the mechanisms of action of carbonic anhydrase inhibitors in muscle excitability disorders. (Pubmed Central) - Oct 13, 2021
These results suggest that carbonic anhydrase inhibitors can reduce muscle excitability by increasing ClC-1 channel activity, probably through intracellular acidification. Such a mechanism may contribute in part to the clinical effects of these drugs in myotonia and other muscle excitability disorders.
- || Keveyis (dichlorphenamide) / Strongbridge
Clinical, Journal: Long-term efficacy and safety of dichlorphenamide for treatment of primary periodic paralysis. (Pubmed Central) - Sep 23, 2021
P3
Tolerability issues (paresthesia, cognition-related AEs) were manageable in most patients. ClinicalTrials.gov identifier NCT00494507.
- Keveyis (dichlorphenamide) / Strongbridge
[VIRTUAL] Clinical experience with Dichlorphenamide in Refractory Hyperkalemic Periodic Paralysis with SCN4 Gene Mutation. () - Mar 18, 2021 - Abstract #AAN2021AAN_1940;
Acetazolamide was then added which reduced attack rate to 3 per week, lasting several hours. This study demonstrated successful response to dichlorphenamide in a patient with treatment refractory hyperkalemic periodic paralysis with SCN4 gene mutation with complete resolution of attacks for over 2 year time period.
- Keveyis (dichlorphenamide) / Strongbridge
[VIRTUAL] Marked Reduction in Paralytic Attacks in Patient With Andersen-Tawil Syndrome Switched From Acetazolamide to Dichlorphenamide: A Case Report () - Mar 18, 2021 - Abstract #AAN2021AAN_1939;
Arrhythmias are currently controlled by a regimen of imipramine and a beta-blocker; the patient also has an implantable cardioverter-defibrillator. In this 24-year-old woman with ATS, switching from AZM to DCP provided marked reduction in the frequency and severity of PP and notable improvements in functioning, with no observed adverse effects.
- || Keveyis (dichlorphenamide) / Strongbridge
Review, Journal: Structure-activity relationship of human carbonic anhydrase-II inhibitors: Detailed insight for future development as anti-glaucoma agents. (Pubmed Central) - Mar 9, 2021
It gave a complete insight into the relationship between their structure-activity and hCA-II inhibition. The broad spectrum of our investigation may help researchers to summarize all the crucial structural information required for the development of more potent hCA-II inhibitors for glaucoma.
- | Flagyl (metronidazole) / SLA
Journal: A connectivity map-based drug repurposing study and integrative analysis of transcriptomic profiling of SARS-CoV-2 infection. (Pubmed Central) - Dec 22, 2020
Making new drugs remain a lengthy process, so the drug repurposing approach provides an insight into the therapeutics that might be helpful in this pandemic. In this study, pathway enrichment and protein network analysis are also performed, and the effectiveness of some drugs obtained from the CMap analysis has been investigated according to previous researches.
- || Keveyis (dichlorphenamide) / Strongbridge
Clinical, Journal: Efficacy and Safety of Dichlorphenamide for Primary Periodic Paralysis in Adolescents Compared With Adults. (Pubmed Central) - Aug 27, 2020
In this study, pathway enrichment and protein network analysis are also performed, and the effectiveness of some drugs obtained from the CMap analysis has been investigated according to previous researches. Dichlorphenamide was comparably effective and tolerated among a small number of adolescents as well as adults, although types of adverse events differed between groups.
- Keveyis (dichlorphenamide) / Strongbridge
[VIRTUAL] Improvement of strength and muscle MRI with dichlorphenamide in hypokalemic periodic paralysis myopathy: A case report () - Aug 16, 2020 - Abstract #WMS2020WMS_90;
- | Keveyis (dichlorphenamide) / Strongbridge
Journal: Episodic Muscle Disorders. (Pubmed Central) - Apr 22, 2020
Dichlorphenamide was comparably effective and tolerated among a small number of adolescents as well as adults, although types of adverse events differed between groups. This article will help neurologists diagnose and manage episodic muscle disorders and, in particular, the periodic paralyses and the nondystrophic myotonias.
- || Keveyis (dichlorphenamide) / Strongbridge
Clinical, P1 data, PK/PD data, Journal: Open-Label, Dose-Escalation, Phase 1 Study of Safety and Single and Multiple-Dose Pharmacokinetics of Dichlorphenamide in Healthy Volunteers. (Pubmed Central) - Mar 24, 2020
Mean area under the concentration-time curve from time 0 to tau (length of the dosing interval estimated using the trapezoidal method) and maximum observed plasma concentration increased dose-proportionally after multiple doses. The incidence and severity of adverse events (AEs) were dose-related, with at least one mild AE reported among 17%, 17%, and 67% of patients in cohorts A, B, and C, respectively; and at least one mild-to-moderate AE among 100% of subjects in cohorts D, E, and F. One serious AE of rash was reported in cohort F. Eleven subjects discontinued; 10 due to AEs at 400 or 800 mg/day (cohorts E and F), including 100% of cohort F. Hypokalemia contributed to 5 of 6 discontinuations in cohort F (all 800 mg/day).
- Keveyis (dichlorphenamide) / Strongbridge
Pathophysiology, Diagnosis and Management of Primary Periodic Paralysis: Identification of Gaps in Knowledge and Competence Among Neurologists () - Jan 21, 2020 - Abstract #AAN2020AAN_929;
This research yielded important insights into current clinical knowledge and competence gaps of neurologists regarding the pathophysiology, diagnosis, and management of PPP. The results indicated a need for comprehensive education across all areas of PPP.
- | dichlorphenamide / Generic mfg.
Enrollment change: HYP-HOP: Hyper- and Hypokalemic Periodic Paralysis Study (clinicaltrials.gov) - Aug 25, 2013
P3, N=71, Completed, Sponsor: University of Rochester
The results indicated a need for comprehensive education across all areas of PPP. N=140 --> 71
- | dichlorphenamide / Generic mfg.
Trial completion: HYP-HOP: Hyper- and Hypokalemic Periodic Paralysis Study (clinicaltrials.gov) - Aug 25, 2013
P3, N=71, Completed, Sponsor: University of Rochester
N=140 --> 71 Active, not recruiting --> Completed